Liver targeting of compound liposomes mediated by glycyrrhetinic acid derivative receptor and its effect on hepatic stellate cells / 中国中药杂志

The 3-succinate-30-stearyl glycyrrhetinic acid(18-GA-Suc) was inserted into glycyrrhetinic acid(GA)-tanshinone Ⅱ_A(TSN)-salvianolic acid B(Sal B) liposome(GTS-lip) to prepare liver targeting compound liposome(Suc-GTS-lip) mediated by GA receptors. Next, pharmacokinetics and tissue distribution of Suc-GTS-lip and GTS-lip were compared by UPLC, and in vivo imaging tracking of Suc-GTS-lip was conducted. The authors investigated the effect of Suc-GTS-lip on the proliferation inhibition of hepatic stellate cells(HSC) and explored their molecular mechanism of improving liver fibrosis. Pharmacokinetic results showed that the AUC_(Sal B) decreased from(636.06±27.73) μg·h·mL~(-1) to(550.39±12.34) μg·h·mL~(-1), and the AUC_(TSN) decreased from(1.08±0.72) μg·h·mL~(-1) to(0.65±0.04) μg·h·mL~(-1), but the AUC_(GA) increased from(43.64±3.10) μg·h·mL~(-1) to(96.21±3.75) μg·h·mL~(-1). The results of tissue distribution showed that the AUC_(Sal B) and C_(max) of Sal B in the liver of the Suc-GTS-lip group were 10.21 and 4.44 times those of the GTS-lip group, respectively. The liver targeting efficiency of Sal B, TSN, and GA in the Suc-GTS-lip group was 40.66%, 3.06%, and 22.08%, respectively. In vivo imaging studies showed that the modified liposomes tended to accumulate in the liver. MTT results showed that Suc-GTS-lip could significantly inhibit the proliferation of HSC, and RT-PCR results showed that the expression of MMP-1 was significantly increased in all groups, but that of TIMP-1 and TIMP-2 was significantly decreased. The mRNA expressions of collagen-I and collagen-Ⅲ were significantly decreased in all groups. The experimental results showed that Suc-GTS-lip had liver targeting, and it could inhibit the proliferation of HSC and induce their apoptosis, which provided the experimental basis for the targeted treatment of liver fibrosis by Suc-GTS-lip.

Preparation and in vitro studies of polysaccharide modified compound liposomes loaded with paclitaxel and doxorubicin / 中国药科大学学报

The objectives of this study were to prepare polysaccharide modified compound liposomes loaded with paclitaxel (PTX) and doxorubicin (DOX) and characterize their phyisicochemical properties,stability and in vitro release profiles.Both PTX-DOX-Lipo and N-lauryl-O-glycol chitosan (LGC) modified liposomes (PTX-DOX-Lipo-LGC) were successfully prepared,and the morphology of the liposomes was observed by transmission electron microscope (TEM),and particle size and zeta potential were analyzed by dynamic light scattering (DLS).pH and osmotic pressure were also determined.The drug loading and encapsulation efficiency,stability and in vitro release were assayed using high-performance liquid phase.Both PTX-DOX-Lipo and PTX-DOX-Lipo-LGC exhibited spherical shape with smooth surface.The average diameter was about 150 nm.pH value and osmotic pressure were in the range of 5.3-6.1 and 820-870 mOsm/kg,respectively.Both PTX and DOX could be encapsulated in liposomes with high encapsulation efficiency (greater than 90％).Compared with PTX-DOX-Lipo,PTX-DOX-Lipo-LGC exhibited lower leakage,higher stability in serum and more sustained release profiles.Moreover,a quicker release rate was observed in pH 5.8 PBS compared with pH 7.4 PBS.PTX-DOX-Lipo-LGC with high drug loading,good stability and sustained drug release profiles has a wide prospect in future clinical application.